Robin Jones, MBBS, MRCP, MD, Royal Marsden NHS Foundation Trust, London, UK, discusses a NAVIGATOR Phase I trial (NCT02508532) that evaluated the efficacy, tolerability and overall survival (OS) of avapritinib in patients with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumor (GIST). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
